Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
Oct. 31, 2020
USD ($)
|
Aug. 31, 2020
USD ($)
|
Mar. 31, 2020
USD ($)
|
Feb. 29, 2020
USD ($)
|
Sep. 30, 2019
USD ($)
|
May 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Aug. 31, 2018
USD ($)
|
Jul. 31, 2018
Program
|
Sep. 30, 2017
USD ($)
|
Aug. 31, 2017
USD ($)
Program
|
Jun. 30, 2016
USD ($)
|
Mar. 31, 2015
USD ($)
|
Sep. 30, 2014
USD ($)
|
May 31, 2014
USD ($)
|
Mar. 31, 2021
USD ($)
|
Mar. 31, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contingent payments of embedded derivative and related liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
$ 200,000
|
| 2019 EMD Serono Supply Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000,000.0
|
|
1,000,000.0
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
$ 2,000,000.0
|
|
| The Leukemia & Lymphoma Society, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research development and commercialization agreement termination period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12 years
|
|
|
| Research development and commercialization agreement termination description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The LLS Agreement terminates upon the earlier of (a) fulfillment of all payment obligations by both parties or (b) 12 years after the effective date. LLS may terminate the LLS Agreement at any time with 60 days’ prior written notice. Either the Company or LLS has the right to terminate the LLS Agreement based on the other party’s uncured material breach.
|
|
|
| BMS Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of programs advancing through preclinical development | Program |
|
|
|
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
| Upfront, nonrefundable payment received |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 83,100,000
|
|
|
|
|
| Contingent payment received |
|
|
|
|
|
|
|
|
|
|
|
|
$ 15,000,000.0
|
|
|
|
|
|
| Milestone payment received |
|
|
|
|
|
|
|
|
|
|
|
$ 25,000,000.0
|
|
|
|
|
|
|
| Additional milestone payment received |
|
|
|
|
|
|
|
|
|
|
|
$ 10,000,000.0
|
|
|
|
|
|
|
| Option fee payment received |
|
|
|
|
|
|
|
|
|
|
$ 12,500,000
|
|
|
|
|
|
|
|
| Milestone revenue recognized |
|
|
|
|
|
|
$ 10,000,000.0
|
|
|
$ 10,000,000.0
|
|
|
|
|
|
|
|
|
| Contingent payments |
|
|
|
|
|
$ 275,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
| Option maintenance fee |
|
|
|
|
|
|
|
|
|
|
12,500,000
|
|
|
|
|
|
|
|
| Deferred revenue |
|
|
|
|
|
|
|
|
|
|
8,200,000
|
|
|
|
|
$ 0
|
|
0
|
| Revenue, remaining performance obligation, amount |
|
|
|
|
|
|
|
|
|
|
20,700,000
|
|
|
|
|
|
|
|
| BMS Agreement | First Performance Obligation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue, remaining performance obligation, amount |
|
|
|
|
|
|
|
|
|
|
8,200,000
|
|
|
|
|
|
|
|
| BMS Agreement | Future Services on Collaboration Joint Steering Committee ("JSC") |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue, remaining performance obligation, amount |
|
|
|
|
|
|
|
|
|
|
200,000
|
|
|
|
|
|
|
|
| BMS Agreement | Third Performance Obligation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue, remaining performance obligation, amount |
|
|
|
|
|
|
|
|
|
|
$ 12,300,000
|
|
|
|
|
|
|
|
| Partially Unsatisfied Performance Obligations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
1,000,000.0
|
|
| Research and Development Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
300,000
|
100,000
|
|
| Research and Development Services | EMD Serono |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
300,000
|
|
| Research and Development Services | Vaxcyte |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pass-through costs from CMOs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
| 2018 BMS Master Services Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500,000
|
|
1,200,000
|
| Other revenue-related parties |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
900,000
|
900,000
|
|
| 2018 Merck Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,400,000
|
|
18,500,000
|
| 2018 Merck Agreement | Merck Sharp & Dohme Corp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of research programs | Program |
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
| Upfront payment received |
|
|
|
|
|
|
|
$ 60,000,000.0
|
|
|
|
|
|
|
|
60,000,000.0
|
|
|
| Revenue from first performance obligation |
|
|
|
|
|
|
|
7,300,000
|
|
|
|
|
|
|
|
|
|
|
| Recognition of up front payment |
|
|
|
|
|
|
|
47,100,000
|
|
|
|
|
|
|
|
|
|
|
| Revenue performance obligation amounts recognized in revenues |
|
|
|
|
|
|
|
700,000
|
|
|
|
|
|
|
|
|
|
|
| Extension option fee associated with contingent program |
|
|
|
|
|
|
|
4,900,000
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in revenue |
|
|
$ (5,100,000)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Embedded interest associated with upfront payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
600,000
|
|
| FTE Funding Received |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,200,000
|
1,300,000
|
|
| Revenue recognition aggregate contingent payments eligible to receive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 500,000,000
|
|
|
| Milestone method revenue recognition description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
If one or more products from each of the target programs are developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate milestone payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.
|
|
|
| 2018 Merck Agreement | Merck Sharp & Dohme Corp | First Target Program |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in revenue |
|
|
(6,200,000)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 Merck Agreement | Merck Sharp & Dohme Corp | Second Target Program |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Increase (decrease) in revenue |
|
|
1,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 Merck Agreement | Merck Sharp & Dohme Corp | Partially Unsatisfied Performance Obligations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,100,000
|
900,000
|
|
| 2018 Merck Agreement | Merck Sharp & Dohme Corp | Accounting Standards Update 2014-09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total interest of unearned revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,300,000
|
|
|
| First Cytokine-Derivative Program | Merck Sharp & Dohme Corp |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront payment received |
|
|
5,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recognition of up front payment |
|
|
$ 50,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,500,000
|
|
| Extended research term |
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Transaction price |
|
|
$ 65,000,000.0
|
$ 60,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Constrained variable consideration |
|
|
|
$ 5,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue reallocated property rights |
|
|
7,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Incremental revenue recognized reallocated target programs |
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated service period |
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Incremental revenue recognized |
|
|
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustments to transaction price |
|
|
$ 5,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cumulative catch-up in revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000.0
|
|
| 2020 Merck Master Services Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,400,000
|
|
|
| Collaboration Agreement | EMD Serono |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Up-front, nonrefundable and non-creditable payment received |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000,000.0
|
|
|
|
| MDA Agreement | EMD Serono |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contingent payment received |
|
|
|
|
$ 1,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payment received |
$ 1,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone revenue recognized |
|
$ 1,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
$ 0
|
| Up-front, nonrefundable and non-creditable payment received |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000,000.0
|
|
|
|
|
| Maximum amount eligible to receive for each product developed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52,500,000
|
|
|
| Supply Agreement | Vaxcyte |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,300,000
|
$ 36,000
|
|
| Research Development and Commercialization Agreement | The Leukemia & Lymphoma Society, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payment received |
|
|
|
|
|
|
|
1,000,000.0
|
|
|
|
|
|
|
|
|
|
|
| Maximum contribution in clinical development |
|
|
|
|
|
|
|
6,000,000.0
|
|
|
|
|
|
|
|
|
|
|
| Initial milestone payment |
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
| Maximum aggregate payment |
|
|
|
|
|
|
|
$ 19,500,000
|
|
|
|
|
|
|
|
|
|
|